Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
Healthcare
$7.22 +2.21%
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
52W Low $3.03High $7.90
Volume 0.45M
Average 0.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$41.80M
FY 2025 · Annual
+7.4% YoYInvesting Cash Flow
-$36.19M
FY 2025 · Annual
Financing Cash Flow
-$45.20M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Deferred Income Tax | 0 | 0 | 0 | (7.08M) | 3.25M |
| Stock-Based Compensation | 32.63M | 11.83M | 10.25M | 8.25M | 6.94M |
| Change in Working Capital | (1.31M) | (44.5M) | (17.85M) | (3.54M) | (10.08M) |
| Accounts Receivables | (5.98M) | (7.82M) | (8.37M) | 16.35M | (21.28M) |
| Inventory | (3.66M) | 2.58M | (2.55M) | (1.64M) | 3.21M |
| Accounts Payables | (902K) | (4.73M) | 449K | (1.38M) | (453K) |
| Other Working Capital | 9.23M | (34.52M) | (7.38M) | (16.86M) | 8.45M |
| Other Non-Cash Items | 7.15M | 7M | 1.51M | (519K) | (358K) |
| Operating Cash Flow | 20.65M | (15.83M) | 27.01M | 38.92M | 41.8M |
| Capital Expenditures | 0 | (7M) | (12.64M) | (56K) | (71K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.07M) | (4.84M) | (23.81M) | (76.23M) | (108.14M) |
| Sales of Investments | 27.19M | 18.94M | 17.33M | 55.85M | 72.02M |
| Other Investing Activities | 0 | 0 | (12.5M) | 0 | 0 |
| Investing Cash Flow | (10.88M) | 7.1M | (19.13M) | (20.44M) | (36.19M) |
| Debt Repayment | (1.5M) | 0 | 0 | (33.33M) | (44.44M) |
| Common Stock Issued | 0 | 12.5M | 0 | 150K | 130K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30.43M) | (277K) | 0 | (666K) | (888K) |
| Financing Cash Flow | (31.93M) | 12.22M | 0 | (33.85M) | (45.2M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.16M) | 3.5M | 7.88M | (15.37M) | (39.58M) |
| Free Cash Flow | 20.65M | (22.83M) | 14.37M | 38.86M | 41.73M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$31.1M
+ D&A$10.9M
+ Stock-Based Comp$6.9M
+ Deferred Tax$3.2M
- Working Capital-$10.1M
- Other Non-Cash-$358.0K
= Operating Cash Flow$41.8M
- Capex-$71.0K
= Free Cash Flow$41.7M
Analysis
FY2025 free cash flow is $41.7M. FCF conversion is 134.1% of net income. Operating cash flow was $41.8M, with capex of -$71.0K. The largest bridge item is D&A at $10.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 16, 2026 |
Does PBYI generate free cash flow?
Puma Biotechnology, Inc. (PBYI) generated $41.73M of free cash flow in fiscal 2025.
How much operating cash flow does PBYI produce?
Operating cash flow was $41.80M, before capital expenditures of $71,000.00.
Continue the stock analysis
Jump to another research area for this company.